KAN-101

Anokion Announces Publication in The Lancet Gastroenterology & Hepatology Highlighting Safety and Preliminary Effects of KAN-101 in Celiac Disease in its ACeD Phase 1 Clinical Trial

06/22/2023

KAN-101 represents the first agent to modulate the IL-2 biomarker associated with symptomatic responses to gluten exposure in celiac patients KAN-101 advancing in a Phase 1b/2 clinical trial in celiac disease and immune tolerance Excerpt from the Press Release: CAMBRIDGE, Mass. & LAUSANNE, Switzerland–(BUSINESS WIRE)–Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease…

Read More

Anokion Announces Presentation of Data from Phase 1 ACeD Clinical Trial Evaluating KAN-101 as a Treatment for Celiac Disease at the 19th International Celiac Disease Symposium

10/28/2022

Positive Phase 1 Data Support Near-term Initiation of Global Phase 2 Trial Excerpt from the Press Release: CAMBRIDGE, Mass. & LAUSANNE, Switzerland–(BUSINESS WIRE)–Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced that data from the Phase 1 ACeD (Assessment of KAN-101 in Celiac Disease) clinical trial…

Read More

Recent Updates

Categories

Archives

RSS Feed